- Report
- November 2025
- 182 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- November 2025
- 188 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- November 2025
- 191 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- October 2025
- 187 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- October 2025
- 194 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- October 2025
- 188 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- October 2025
- 192 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- August 2025
- 193 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- December 2025
- 276 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 385 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- December 2025
- 278 Pages
Global
From €5160EUR$5,850USD£4,533GBP
- Report
- November 2025
- 121 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- October 2025
- 250 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- November 2025
- 160 Pages
Global
From €2962EUR$3,358USD£2,602GBP
€3484EUR$3,950USD£3,061GBP
- Report
- June 2025
- 122 Pages
Asia Pacific
From €3528EUR$4,000USD£3,100GBP
- Report
- November 2022
- 295 Pages
Global
From €4366EUR$4,950USD£3,836GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €7939EUR$9,000USD£6,974GBP
- Report
- September 2023
- 270 Pages
Global
From €3683EUR$4,175USD£3,235GBP
- Report
- March 2019
- 255 Pages
Global
From €2183EUR$2,475USD£1,918GBP
- Report
- February 2024
- 75 Pages
Global
From €4366EUR$4,950USD£3,836GBP

The Tumor Profiling market within the Diagnostics industry is a rapidly growing sector. It involves the use of advanced technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to analyze the genetic makeup of tumors. This helps to identify the specific mutations that are driving the tumor's growth, allowing for more targeted treatments. Tumor profiling can also be used to monitor the effectiveness of treatments and to detect recurrence of the tumor.
The market is driven by the increasing prevalence of cancer, the growing demand for personalized medicine, and the development of new technologies. Additionally, the increasing availability of genomic data and the development of artificial intelligence (AI) and machine learning (ML) are expected to further drive the market.
Some of the major companies in the Tumor Profiling market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and Roche. Show Less Read more